^
CANCER:

Endometrial Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
MSI-H/dMMR + MLH1 deletion
Endometrial Cancer
dostarlimab
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
MSH2 deletion + MSH6 deletion
Endometrial Cancer
dostarlimab
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
MLH1 deletion+ PMS2 deletion
Endometrial Cancer
dostarlimab
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
MSI-H/dMMR
Endometrial Cancer
dostarlimab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
ALPP expression
Endometrial Cancer
anti-ALPP CAR-T cells
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive
:
A2
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Endometrial Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Endometrial Cancer
larotrectinib
Sensitive
:
A2
No biomarker
Endometrial Cancer
cisplatin + paclitaxel + SGN-15
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
larotrectinib
Sensitive
:
A2
No biomarker
Endometrial Cancer
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
docetaxel
Sensitive
:
A2
HER-2 positive
Endometrial Cancer
trastuzumab
Sensitive
:
A2
TMB-H
Endometrial Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Endometrial Cancer
cisplatin + ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
paclitaxel + ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
topotecan
Sensitive
:
A2
No biomarker
Endometrial Cancer
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
cisplatin + SGN-15
Sensitive
:
A2
No biomarker
Endometrial Cancer
pegylated liposomal doxorubicin
Sensitive
:
A2
No biomarker
Endometrial Cancer
SGN-15
Sensitive
:
A2
No biomarker
Endometrial Cancer
carboplatin
Sensitive
:
A2
No biomarker
Endometrial Cancer
cisplatin
Sensitive
:
A2
No biomarker
Endometrial Cancer
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
temsirolimus
Sensitive
:
A2
No biomarker
Endometrial Cancer
bevacizumab
Sensitive
:
A2
NTRK3 fusion
Endometrial Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Endometrial Cancer
entrectinib
Sensitive
:
A2
No biomarker
Endometrial Cancer
tamoxifen + medroxyprogesterone
Sensitive
:
A2
No biomarker
Endometrial Cancer
tamoxifen
Sensitive
:
A2
No biomarker
Endometrial Cancer
nivolumab
Sensitive
:
A2
No biomarker
Endometrial Cancer
fulvestrant
Sensitive
:
A2